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David P. SteensmaWise mariners—veteran sailors who understand
that waves are not measured in feet or in fathoms,
but in increments of fear—always ensure that their ves-
sels are fit before setting out on a long ocean voyage:
hull sound, brightwork polished, adequate provisions
laid down, lines and cordage clean, navigation equip-
ment in good repair. Because the sea itself is beyond in-
dividual human influence, those who make their living
by going down to the water have learned to control all
those factors that are amenable to manipulation. Sim-
ilarly, events after an allogeneic hematopoietic stem
cell transplant (ASCT) procedure are as unpredictable
as the weather of the notorious Southern Ocean, about
which the old salts say, ‘‘Below 50 degrees South lati-
tude there is no law; below 60 degrees, there is no
God.’’Wise physicians, therefore, ensure that their pa-
tients are always physiologically ‘‘ship-shape and Bris-
tol fashion’’ before sending them off in search of the
fabled Land of Cure, somewhere beyond the ASCT
horizon.
Despite the advent of effective drug therapies that
can improve blood counts and extend the life of some
patients who have myelodysplastic syndromes
(MDS), ASCT remains the only definitive, potentially
curative therapy for this difficult group of marrow
failure syndromes [1]. Unfortunately, because the
median age of patients diagnosed with MDS is ap-
proximately 71 years, only a small subset of patients
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dergo the procedure [2]. Each year, at least 25,000
people in the United States will learn that they have
MDS [3]. Yet according to data submitted to the
Center for International Blood and Marrow Trans-
plantation Research, fewer than 1000 patients under-
went ASCT in the United States for MDS-related
indications in 2011 [4].
Among those patients with MDS who do brave
the deep waters of ASCT, most will receive
reduced-intensity conditioning (RIC) before stem
cell infusion, relying entirely upon the ‘‘graft-ver-
sus-leukemia’’ (GVL) immunological activity of the
allograft to eradicate stubborn neoplastic MDS he-
matopoietic clones [5,6]. It is now clear that long-
term ASCT outcomes in MDS are comparable with
traditional myeloablative and newer RIC condition-
ing [7]. But a few retrospective studies have suggested
that particularly with RIC ASCT, the less ‘‘clean-up
work’’ that the graft has to do—that is to say, the
fewer clonal cells that are present at the time of the
transplantation and the lower the burden of residual
disease—the more likely it is that the transplantation
will be successful [8,9]. Just as for acute myelogenous
leukemia, we now know from ongoing whole-genome
sequencing efforts that 85% of the marrow cells in
MDS are clonal and bear somatic mutations, even
among the subset of patients with MDS who do not
have excess blasts, highlighting both the danger in
routinely relying on GVL and the widespread need
for pre-ASCT cytoreduction [10].
The fact that most hematopoietic elements are
clonal in MDS marrow raises the interesting possibil-
ity that all patients with MDS should undergo cytore-
ductive therapy before ASCT regardless of blast
proportion, but such an approach is not uniformly
practiced. Perhaps as a result, relapse (with subsequent
complications ofMDS-related cytopenias) remains the
most frequent cause of death in patients with MDS
who have undergone ASCT, and this sober fact is
true regardless of how many blasts the patient had in
the marrow before transplantation [11].1145
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pretransplantation approach in patients with \10%
blasts. In the meantime, most patients with excess
blasts do undergo cytoreductive therapy of one sort
or another before ASCT, both to serve as a ‘‘bridge
to transplantation’’ and to optimize the patient’s mar-
row milieu. Unfortunately, traditional intensive che-
motherapy (IC) cytoreductive strategies, such as the
classic ‘‘3 & 7’’ anthracycline/cytarabine combination,
are a tough upwind beat for many patients, and serious
and durable adverse events from IC (or general disgust
with the limitations of contemporary therapy, leading
to a minimalist mindset) can prevent an otherwise suit-
able candidate from ever reaching ASCT [12].
In recent years, there has been great interest in ef-
fective pretransplantation therapies that are less toxic
than ICbut thatmight still achieve the same ends.Clin-
ical practice is shifting toward the use of the hy-
pomethylating agents (ie, DNA methyltransferase
inhibitors), either azacitidine or its chemical cousin
decitabine, for this purpose, and a number of small
studies have demonstrated the feasibility of pre-
ASCT hypomethylating agent therapy [13-17].
Azacitidine and decitabine achieve cytoreduction less
rapidly than IC, but it seems that with these agents,
the marrow response rate is still high enough and on-
treatmentmortality is lowenough to justify routine use.
If hypomethylating agents are safer than and nearly
as effective as IC, should they supplant IC as the pre-
ferred pre-ASCT cytoreductive therapy in patients
with MDS? The only way to confirm the optimal pre-
paratory regimen before ASCT in these patients would
be to do a randomized prospective trial comparing no
pretransplantation therapy with either azacitidine/
decitabine or IC followed by ASCT, with stratification
by baseline blast proportion and other known MDS-
associated prognostic factors (the list of these is rapidly
expanding) [18]. However, the number of study sub-
jects required to detect the probable small mortality
difference between these 3 conditioning approaches
would be quite large—several hundred patients at
least, depending on how pessimistic the biostatistical
assumptions are about the proportion of randomized
patients who would stay on such a study long enough
to undergo ASCT.
Such prospective transplantation trials are notori-
ously difficult to conduct. Perhaps the Germans could
complete such a study, as German hematological ma-
lignancy study groups have proved in recent years
that they can accomplish almost anything, including
an ongoing randomized trial of azacitidine as primary
therapy versus azacitidine followed by ASCT in MDS
(http://clinicaltrials.gov/ct2/show/NCT01404741). But
a 3-arm trial along the lines of that described that is
large enough to answer the question of the optimal
ASCT preconditioning preparatory regimen seems
unlikely to occur.We are left, then, with retrospective comparisons
between IC and other preconditioning cytoreductive
approaches, such as the new analysis by Aaron Gerds
et al. [19] from the Fred Hutchinson Cancer Research
Center (FHCRC) in Seattle that publishes in this issue
of Biology of Blood and Marrow Transplantation. The
FHCRC investigators compared 35 patients with
MDS who underwent azacitidine therapy before
ASCT from 2004 to 2010 with 33 patients with
MDS who received IC before ASCT between 1992
and 2002. All of the patients undergoing IC received
a myeloablative ASCT, whereas 60% of those in the
azacitidine cohort underwent RIC ASCT. Once
disease-associated prognostic markers were accounted
for, the FHCRC investigators observed no differences
between the 2 cohorts in overall survival, relapse mor-
tality, or nonrelapse mortality, confirming the feasibil-
ity of either preconditioning approach.
Although these retrospective data are all we have to
work with, they are difficult to draw general conclu-
sions from, because the patients were treated in differ-
ent eras on a wide variety of distinct ASCT protocols.
The FHCRC MDS ASCT experience is large com-
pared to other centers, but as the investigators ac-
knowledge, this study was powered such that only
a dramatic difference in outcomes between azacitidine
and IC could have been observed. Of note, the older
age of patients taking azacitidine in the series (median
of 60 years versus 47 for IC) would suggest a trend for
the azacitidine-treated patients to have poorer out-
comes, but the opposite was true—a point in favor of
azacitidine.
As a practical matter, azanucleoside therapy offers
the attraction of a relatively nontoxic outpatient bridge
to ASCT, and hematology-oncology clinicians are al-
ready showing that they believe by using azacitidine
and decitabine widely in this role outside the context
of a clinical study. Even when a patient is recognized
as an excellent transplantation candidate from the day
of MDS diagnosis and promptly referred for a trans-
plantation consultation, and even when the patient
comes to the initial consultation accompanied by a clus-
ter of healthy siblings the size of an America’s Cup
crew, all eager to be tissue typed immediately, ASCT
does not happen overnight. There is certain activation
energy: A suitable donor must be identified, insurers
may need some persuasion to pay for the procedure,
and pretransplantation screening tests must be com-
pleted. While all this is ongoing, azanucleosides can
keep the patient’s disease temporarily becalmed.
Azacitidine and decitabine are thought to exert
their clinical activity by altering epigenetic patterns
and consequently reactivating aberrantly silenced tu-
mor suppressor genes [20]. However, recently, hypo-
methylating agents have also been found to modulate
the number and activity of T cell subsets, including im-
munomodulatory regulatory T cells, by up-regulating
Biol Blood Marrow Transplant 18:1145-1149, 2012 1147The Bottom Linetumor-associated antigen expression in post-ASCT
patients [21]. Refinement of such a strategy might
finally help cut GVL free from where it has been
stubbornly fouled on the snag of graft-versus-host
disease, thereby improving ASCT outcomes. Post-
treatment hypomethylating agent therapy might also
directly act on persistent neoplastic clones that escape
GVL, delaying relapse [22].
Experienced seamen have learned that the sea is
a relentless test proctor, eventually detecting every
ship and sailor’s failings, probing for anywhere prepa-
ration was skimped. Before bidding bon voyage to our
patients with MDS on their ASCT cruise, we too owe
it to them to ensure that they are as prepared as they
can be for a safe and successful journey. For now, the
study of Gerds et al. [19] indicates that azacitidine
cytoreduction could be an important part of these
plans for send-off, but more data are needed.ACKNOWLEDGMENT
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